Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anakinra for Granulomatous Complications in CGD
NCT04136028Phase 1Completed
- Sponsor
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
- Start
- Sep 2015
- Primary completion
- Jan 2019
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anakinra in chronic granulomatous disease (CGD), sponsored by Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Primary endpoint: Overall Survival at 6 months. Started Sep 2015; status: completed.
02
Drugs
anakinra
03
Conditions
chronic granulomatous disease (CGD)
Beyond the preview
Go deeper on NCT04136028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04136028.